The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Biosimilar Monoclonal Antibodies Market Research Report 2024
Synopsis
Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.
Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.
The global Biosimilar Monoclonal Antibodies market was valued at US$ 4509.2 million in 2023 and is anticipated to reach US$ 12960 million by 2030, witnessing a CAGR of 16.0% during the forecast period 2024-2030.
Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.
Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.
In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.
This report aims to provide a comprehensive presentation of the global market for Biosimilar Monoclonal Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Monoclonal Antibodies.
Report Scope
The Biosimilar Monoclonal Antibodies market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar Monoclonal Antibodies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar Monoclonal Antibodies manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Celltrion
Pfizer (Hospira)
3SBIO
Novartis (Sandoz)
Dr Reddy’s
Celgen Biopharma
Cadila Healthcare
Hisun Pharma
Torrent Pharmaceuticals
Segment by Type
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other
Segment by Application
Oncology
Autoimmune Disease
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biosimilar Monoclonal Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biosimilar Monoclonal Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.
Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.
The global Biosimilar Monoclonal Antibodies market was valued at US$ 4509.2 million in 2023 and is anticipated to reach US$ 12960 million by 2030, witnessing a CAGR of 16.0% during the forecast period 2024-2030.
Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.
Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.
In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.
This report aims to provide a comprehensive presentation of the global market for Biosimilar Monoclonal Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Monoclonal Antibodies.
Report Scope
The Biosimilar Monoclonal Antibodies market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar Monoclonal Antibodies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar Monoclonal Antibodies manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Celltrion
Pfizer (Hospira)
3SBIO
Novartis (Sandoz)
Dr Reddy’s
Celgen Biopharma
Cadila Healthcare
Hisun Pharma
Torrent Pharmaceuticals
Segment by Type
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other
Segment by Application
Oncology
Autoimmune Disease
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biosimilar Monoclonal Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biosimilar Monoclonal Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Biosimilar Monoclonal Antibodies Market Overview
1.1 Product Overview and Scope of Biosimilar Monoclonal Antibodies
1.2 Biosimilar Monoclonal Antibodies Segment by Type
1.2.1 Global Biosimilar Monoclonal Antibodies Market Value Comparison by Type (2024-2030)
1.2.2 Infliximab
1.2.3 Rituximab
1.2.4 Trastuzumab
1.2.5 Adalimumab
1.2.6 Other
1.3 Biosimilar Monoclonal Antibodies Segment by Application
1.3.1 Global Biosimilar Monoclonal Antibodies Market Value by Application: (2024-2030)
1.3.2 Oncology
1.3.3 Autoimmune Disease
1.3.4 Other
1.4 Global Biosimilar Monoclonal Antibodies Market Size Estimates and Forecasts
1.4.1 Global Biosimilar Monoclonal Antibodies Revenue 2019-2030
1.4.2 Global Biosimilar Monoclonal Antibodies Sales 2019-2030
1.4.3 Global Biosimilar Monoclonal Antibodies Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Biosimilar Monoclonal Antibodies Market Competition by Manufacturers
2.1 Global Biosimilar Monoclonal Antibodies Sales Market Share by Manufacturers (2019-2024)
2.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Biosimilar Monoclonal Antibodies Average Price by Manufacturers (2019-2024)
2.4 Global Biosimilar Monoclonal Antibodies Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Biosimilar Monoclonal Antibodies, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biosimilar Monoclonal Antibodies, Product Type & Application
2.7 Biosimilar Monoclonal Antibodies Market Competitive Situation and Trends
2.7.1 Biosimilar Monoclonal Antibodies Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Biosimilar Monoclonal Antibodies Players Market Share by Revenue
2.7.3 Global Biosimilar Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Biosimilar Monoclonal Antibodies Retrospective Market Scenario by Region
3.1 Global Biosimilar Monoclonal Antibodies Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Biosimilar Monoclonal Antibodies Global Biosimilar Monoclonal Antibodies Sales by Region: 2019-2030
3.2.1 Global Biosimilar Monoclonal Antibodies Sales by Region: 2019-2024
3.2.2 Global Biosimilar Monoclonal Antibodies Sales by Region: 2025-2030
3.3 Global Biosimilar Monoclonal Antibodies Global Biosimilar Monoclonal Antibodies Revenue by Region: 2019-2030
3.3.1 Global Biosimilar Monoclonal Antibodies Revenue by Region: 2019-2024
3.3.2 Global Biosimilar Monoclonal Antibodies Revenue by Region: 2025-2030
3.4 North America Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
3.4.1 North America Biosimilar Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Biosimilar Monoclonal Antibodies Sales by Country (2019-2030)
3.4.3 North America Biosimilar Monoclonal Antibodies Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
3.5.1 Europe Biosimilar Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Biosimilar Monoclonal Antibodies Sales by Country (2019-2030)
3.5.3 Europe Biosimilar Monoclonal Antibodies Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
3.6.1 Asia Pacific Biosimilar Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Biosimilar Monoclonal Antibodies Sales by Country (2019-2030)
3.6.3 Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
3.7.1 Latin America Biosimilar Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Biosimilar Monoclonal Antibodies Sales by Country (2019-2030)
3.7.3 Latin America Biosimilar Monoclonal Antibodies Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
3.8.1 Middle East and Africa Biosimilar Monoclonal Antibodies Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2019-2030)
3.8.3 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Biosimilar Monoclonal Antibodies Sales by Type (2019-2030)
4.1.1 Global Biosimilar Monoclonal Antibodies Sales by Type (2019-2024)
4.1.2 Global Biosimilar Monoclonal Antibodies Sales by Type (2025-2030)
4.1.3 Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2019-2030)
4.2 Global Biosimilar Monoclonal Antibodies Revenue by Type (2019-2030)
4.2.1 Global Biosimilar Monoclonal Antibodies Revenue by Type (2019-2024)
4.2.2 Global Biosimilar Monoclonal Antibodies Revenue by Type (2025-2030)
4.2.3 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2019-2030)
4.3 Global Biosimilar Monoclonal Antibodies Price by Type (2019-2030)
5 Segment by Application
5.1 Global Biosimilar Monoclonal Antibodies Sales by Application (2019-2030)
5.1.1 Global Biosimilar Monoclonal Antibodies Sales by Application (2019-2024)
5.1.2 Global Biosimilar Monoclonal Antibodies Sales by Application (2025-2030)
5.1.3 Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2019-2030)
5.2 Global Biosimilar Monoclonal Antibodies Revenue by Application (2019-2030)
5.2.1 Global Biosimilar Monoclonal Antibodies Revenue by Application (2019-2024)
5.2.2 Global Biosimilar Monoclonal Antibodies Revenue by Application (2025-2030)
5.2.3 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2019-2030)
5.3 Global Biosimilar Monoclonal Antibodies Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Celltrion
6.1.1 Celltrion Corporation Information
6.1.2 Celltrion Description and Business Overview
6.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Celltrion Biosimilar Monoclonal Antibodies Product Portfolio
6.1.5 Celltrion Recent Developments/Updates
6.2 Pfizer (Hospira)
6.2.1 Pfizer (Hospira) Corporation Information
6.2.2 Pfizer (Hospira) Description and Business Overview
6.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Portfolio
6.2.5 Pfizer (Hospira) Recent Developments/Updates
6.3 3SBIO
6.3.1 3SBIO Corporation Information
6.3.2 3SBIO Description and Business Overview
6.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
6.3.4 3SBIO Biosimilar Monoclonal Antibodies Product Portfolio
6.3.5 3SBIO Recent Developments/Updates
6.4 Novartis (Sandoz)
6.4.1 Novartis (Sandoz) Corporation Information
6.4.2 Novartis (Sandoz) Description and Business Overview
6.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Portfolio
6.4.5 Novartis (Sandoz) Recent Developments/Updates
6.5 Dr Reddy’s
6.5.1 Dr Reddy’s Corporation Information
6.5.2 Dr Reddy’s Description and Business Overview
6.5.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Dr Reddy’s Biosimilar Monoclonal Antibodies Product Portfolio
6.5.5 Dr Reddy’s Recent Developments/Updates
6.6 Celgen Biopharma
6.6.1 Celgen Biopharma Corporation Information
6.6.2 Celgen Biopharma Description and Business Overview
6.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Product Portfolio
6.6.5 Celgen Biopharma Recent Developments/Updates
6.7 Cadila Healthcare
6.6.1 Cadila Healthcare Corporation Information
6.6.2 Cadila Healthcare Description and Business Overview
6.6.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Product Portfolio
6.7.5 Cadila Healthcare Recent Developments/Updates
6.8 Hisun Pharma
6.8.1 Hisun Pharma Corporation Information
6.8.2 Hisun Pharma Description and Business Overview
6.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Product Portfolio
6.8.5 Hisun Pharma Recent Developments/Updates
6.9 Torrent Pharmaceuticals
6.9.1 Torrent Pharmaceuticals Corporation Information
6.9.2 Torrent Pharmaceuticals Description and Business Overview
6.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Portfolio
6.9.5 Torrent Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Biosimilar Monoclonal Antibodies Industry Chain Analysis
7.2 Biosimilar Monoclonal Antibodies Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biosimilar Monoclonal Antibodies Production Mode & Process
7.4 Biosimilar Monoclonal Antibodies Sales and Marketing
7.4.1 Biosimilar Monoclonal Antibodies Sales Channels
7.4.2 Biosimilar Monoclonal Antibodies Distributors
7.5 Biosimilar Monoclonal Antibodies Customers
8 Biosimilar Monoclonal Antibodies Market Dynamics
8.1 Biosimilar Monoclonal Antibodies Industry Trends
8.2 Biosimilar Monoclonal Antibodies Market Drivers
8.3 Biosimilar Monoclonal Antibodies Market Challenges
8.4 Biosimilar Monoclonal Antibodies Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Biosimilar Monoclonal Antibodies Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Biosimilar Monoclonal Antibodies Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Biosimilar Monoclonal Antibodies Market Competitive Situation by Manufacturers in 2023
Table 4. Global Biosimilar Monoclonal Antibodies Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Biosimilar Monoclonal Antibodies Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Biosimilar Monoclonal Antibodies Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Biosimilar Monoclonal Antibodies Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Biosimilar Monoclonal Antibodies Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Biosimilar Monoclonal Antibodies, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Biosimilar Monoclonal Antibodies, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Biosimilar Monoclonal Antibodies, Product Type & Application
Table 12. Global Key Manufacturers of Biosimilar Monoclonal Antibodies, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Biosimilar Monoclonal Antibodies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Monoclonal Antibodies as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Biosimilar Monoclonal Antibodies Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Biosimilar Monoclonal Antibodies Sales by Region (2019-2024) & (K Units)
Table 18. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2019-2024)
Table 19. Global Biosimilar Monoclonal Antibodies Sales by Region (2025-2030) & (K Units)
Table 20. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2025-2030)
Table 21. Global Biosimilar Monoclonal Antibodies Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2019-2024)
Table 23. Global Biosimilar Monoclonal Antibodies Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2025-2030)
Table 25. North America Biosimilar Monoclonal Antibodies Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Biosimilar Monoclonal Antibodies Sales by Country (2019-2024) & (K Units)
Table 27. North America Biosimilar Monoclonal Antibodies Sales by Country (2025-2030) & (K Units)
Table 28. North America Biosimilar Monoclonal Antibodies Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Biosimilar Monoclonal Antibodies Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Biosimilar Monoclonal Antibodies Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Biosimilar Monoclonal Antibodies Sales by Country (2019-2024) & (K Units)
Table 32. Europe Biosimilar Monoclonal Antibodies Sales by Country (2025-2030) & (K Units)
Table 33. Europe Biosimilar Monoclonal Antibodies Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Biosimilar Monoclonal Antibodies Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Biosimilar Monoclonal Antibodies Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Biosimilar Monoclonal Antibodies Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Biosimilar Monoclonal Antibodies Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Biosimilar Monoclonal Antibodies Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Biosimilar Monoclonal Antibodies Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Biosimilar Monoclonal Antibodies Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Biosimilar Monoclonal Antibodies Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Biosimilar Monoclonal Antibodies Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Biosimilar Monoclonal Antibodies Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Biosimilar Monoclonal Antibodies Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Biosimilar Monoclonal Antibodies Sales (K Units) by Type (2019-2024)
Table 51. Global Biosimilar Monoclonal Antibodies Sales (K Units) by Type (2025-2030)
Table 52. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2019-2024)
Table 53. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2025-2030)
Table 54. Global Biosimilar Monoclonal Antibodies Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Biosimilar Monoclonal Antibodies Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2019-2024)
Table 57. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2025-2030)
Table 58. Global Biosimilar Monoclonal Antibodies Price (USD/Unit) by Type (2019-2024)
Table 59. Global Biosimilar Monoclonal Antibodies Price (USD/Unit) by Type (2025-2030)
Table 60. Global Biosimilar Monoclonal Antibodies Sales (K Units) by Application (2019-2024)
Table 61. Global Biosimilar Monoclonal Antibodies Sales (K Units) by Application (2025-2030)
Table 62. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2019-2024)
Table 63. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2025-2030)
Table 64. Global Biosimilar Monoclonal Antibodies Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Biosimilar Monoclonal Antibodies Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2019-2024)
Table 67. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2025-2030)
Table 68. Global Biosimilar Monoclonal Antibodies Price (USD/Unit) by Application (2019-2024)
Table 69. Global Biosimilar Monoclonal Antibodies Price (USD/Unit) by Application (2025-2030)
Table 70. Celltrion Corporation Information
Table 71. Celltrion Description and Business Overview
Table 72. Celltrion Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 73. Celltrion Biosimilar Monoclonal Antibodies Product
Table 74. Celltrion Recent Developments/Updates
Table 75. Pfizer (Hospira) Corporation Information
Table 76. Pfizer (Hospira) Description and Business Overview
Table 77. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 78. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product
Table 79. Pfizer (Hospira) Recent Developments/Updates
Table 80. 3SBIO Corporation Information
Table 81. 3SBIO Description and Business Overview
Table 82. 3SBIO Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. 3SBIO Biosimilar Monoclonal Antibodies Product
Table 84. 3SBIO Recent Developments/Updates
Table 85. Novartis (Sandoz) Corporation Information
Table 86. Novartis (Sandoz) Description and Business Overview
Table 87. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product
Table 89. Novartis (Sandoz) Recent Developments/Updates
Table 90. Dr Reddy’s Corporation Information
Table 91. Dr Reddy’s Description and Business Overview
Table 92. Dr Reddy’s Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Dr Reddy’s Biosimilar Monoclonal Antibodies Product
Table 94. Dr Reddy’s Recent Developments/Updates
Table 95. Celgen Biopharma Corporation Information
Table 96. Celgen Biopharma Description and Business Overview
Table 97. Celgen Biopharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Celgen Biopharma Biosimilar Monoclonal Antibodies Product
Table 99. Celgen Biopharma Recent Developments/Updates
Table 100. Cadila Healthcare Corporation Information
Table 101. Cadila Healthcare Description and Business Overview
Table 102. Cadila Healthcare Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Cadila Healthcare Biosimilar Monoclonal Antibodies Product
Table 104. Cadila Healthcare Recent Developments/Updates
Table 105. Hisun Pharma Corporation Information
Table 106. Hisun Pharma Description and Business Overview
Table 107. Hisun Pharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. Hisun Pharma Biosimilar Monoclonal Antibodies Product
Table 109. Hisun Pharma Recent Developments/Updates
Table 110. Torrent Pharmaceuticals Corporation Information
Table 111. Torrent Pharmaceuticals Description and Business Overview
Table 112. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product
Table 114. Torrent Pharmaceuticals Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. Biosimilar Monoclonal Antibodies Distributors List
Table 118. Biosimilar Monoclonal Antibodies Customers List
Table 119. Biosimilar Monoclonal Antibodies Market Trends
Table 120. Biosimilar Monoclonal Antibodies Market Drivers
Table 121. Biosimilar Monoclonal Antibodies Market Challenges
Table 122. Biosimilar Monoclonal Antibodies Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Biosimilar Monoclonal Antibodies
Figure 2. Global Biosimilar Monoclonal Antibodies Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Biosimilar Monoclonal Antibodies Market Share by Type in 2023 & 2030
Figure 4. Infliximab Product Picture
Figure 5. Rituximab Product Picture
Figure 6. Trastuzumab Product Picture
Figure 7. Adalimumab Product Picture
Figure 8. Other Product Picture
Figure 9. Global Biosimilar Monoclonal Antibodies Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global Biosimilar Monoclonal Antibodies Market Share by Application in 2023 & 2030
Figure 11. Oncology
Figure 12. Autoimmune Disease
Figure 13. Other
Figure 14. Global Biosimilar Monoclonal Antibodies Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Biosimilar Monoclonal Antibodies Market Size (2019-2030) & (US$ Million)
Figure 16. Global Biosimilar Monoclonal Antibodies Sales (2019-2030) & (K Units)
Figure 17. Global Biosimilar Monoclonal Antibodies Average Price (USD/Unit) & (2019-2030)
Figure 18. Biosimilar Monoclonal Antibodies Report Years Considered
Figure 19. Biosimilar Monoclonal Antibodies Sales Share by Manufacturers in 2023
Figure 20. Global Biosimilar Monoclonal Antibodies Revenue Share by Manufacturers in 2023
Figure 21. The Global 5 and 10 Largest Biosimilar Monoclonal Antibodies Players: Market Share by Revenue in 2023
Figure 22. Biosimilar Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 23. Global Biosimilar Monoclonal Antibodies Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 24. North America Biosimilar Monoclonal Antibodies Sales Market Share by Country (2019-2030)
Figure 25. North America Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2019-2030)
Figure 26. U.S. Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Canada Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Country (2019-2030)
Figure 29. Europe Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2019-2030)
Figure 30. Germany Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. France Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. U.K. Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Italy Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Russia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Asia Pacific Biosimilar Monoclonal Antibodies Sales Market Share by Region (2019-2030)
Figure 36. Asia Pacific Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2019-2030)
Figure 37. China Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Japan Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. South Korea Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. India Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Australia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Taiwan Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Indonesia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Thailand Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Malaysia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Philippines Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Latin America Biosimilar Monoclonal Antibodies Sales Market Share by Country (2019-2030)
Figure 48. Latin America Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2019-2030)
Figure 49. Mexico Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Brazil Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Argentina Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Market Share by Country (2019-2030)
Figure 53. Middle East & Africa Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2019-2030)
Figure 54. Turkey Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Saudi Arabia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. U.A.E Biosimilar Monoclonal Antibodies Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 57. Global Sales Market Share of Biosimilar Monoclonal Antibodies by Type (2019-2030)
Figure 58. Global Revenue Market Share of Biosimilar Monoclonal Antibodies by Type (2019-2030)
Figure 59. Global Biosimilar Monoclonal Antibodies Price (USD/Unit) by Type (2019-2030)
Figure 60. Global Sales Market Share of Biosimilar Monoclonal Antibodies by Application (2019-2030)
Figure 61. Global Revenue Market Share of Biosimilar Monoclonal Antibodies by Application (2019-2030)
Figure 62. Global Biosimilar Monoclonal Antibodies Price (USD/Unit) by Application (2019-2030)
Figure 63. Biosimilar Monoclonal Antibodies Value Chain
Figure 64. Biosimilar Monoclonal Antibodies Production Process
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Distributors Profiles
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
